BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2016--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing CODIT™ (Characterized Oral Desensitization
ImmunoTherapy) treatments for life-threatening food
allergies, today announced the closing of the $145 million equity
investment by Nestlé Health Science. Nestlé Health Science purchased
7,552,084 shares of Aimmune's common stock at $19.20 per share on
November 23, 2016, in a private placement transaction. The sale of
shares was made pursuant to the terms of the Securities Purchase
Agreement entered into on November 3, 2016, by Aimmune and Nestlé Health
Science, as previously reported by Aimmune. In connection with the
closing of the equity investment, Greg Behar, Chief Executive Officer of
Nestlé Health Science, was appointed to Aimmune’s board of directors on
November 23, 2016. Aimmune has a total of 50,044,727 shares of common
stock outstanding after taking into account the shares issued to Nestlé
Additional details regarding the equity investment and strategic
collaboration agreement can be found in Aimmune's Form 8-K filed with
the Securities and Exchange Commission on November 4, 2016.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of protection
by desensitizing patients with defined, precise amounts of key
allergens. Aimmune’s first investigational product using CODIT™, AR101
for the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials in ages 4-55. AR101 is a characterized, regulated, oral
biological drug product containing the protein profile found in peanuts.
For more information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161128005138/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.,